MRNS Stock Recent News

MRNS LATEST HEADLINES

MRNS Stock News Image - businesswire.com

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today presented new data from the pivotal Phase 3 RAISE trial evaluating intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE) at the Neurocritical Care Society (NCS) Annual Meeting. Topline data demonstrating that the trial met one of two co-primary endpoints were reported in June.

businesswire.com 2024 Oct 17
MRNS Stock News Image - benzinga.com

Micro-cap stocks can come in many shapes and sizes. Some might be once successful firms that lost their way and are looking to recover their prior glory.

benzinga.com 2024 Oct 16
MRNS Stock News Image - marketbeat.com

Micro-cap stocks can come in many shapes and sizes. Some might be once successful firms that lost their way and are looking to recover their prior glory.

marketbeat.com 2024 Oct 11
MRNS Stock News Image - businesswire.com

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that additional data from the Phase 3 RAISE trial in refractory status epilepticus and retrospective claims-based data from patients with status epilepticus will be presented at the upcoming Neurocritical Care Society (NCS) 22nd Annual Meeting, being held October 14-17 in San Diego, California. Pr.

businesswire.com 2024 Oct 09
MRNS Stock News Image - marketbeat.com

Marinus Pharmaceuticals NASDAQ: MRNS is a micro-cap pharmaceutical stock with multiple Wall Street analysts seeing significant upside. Both Oppenheimer and Cantor Fitzgerald recently issued or reiterated massive price targets for the company.

marketbeat.com 2024 Oct 01
MRNS Stock News Image - businesswire.com

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, will host an Investor and Analyst Day on Friday, September 20 from 9:00 a.m. to 12:00 p.m. Eastern Time in New York and via webcast. The event will feature presentations from Marinus management and key opinion leaders with a focus on the Company's development program for ZTALMY® (ganaxolone) oral suspension CV in.

businesswire.com 2024 Aug 19
MRNS Stock News Image - seekingalpha.com

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Sonya Weigle - Chief People and Investor Relations Officer Scott Braunstein - Chairman and Chief Executive Officer Lisa Lejuwaan - Senior Vice President and Business Unit Lead, Rare Genetic Epilepsy Joseph Hulihan - Chief Medical Officer Steven Pfanstiel - Chief Financial Officer and Chief Operating Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Joseph Thome - TD Cowen Andrew Tsai - Jefferies Douglas Tsao - H.C. Wainwright Marc Goodman - Leerink Operator Greetings and welcome to Marinus Pharmaceuticals' Second Quarter Financial Results and Business Update Call.

seekingalpha.com 2024 Aug 13
MRNS Stock News Image - zacks.com

Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.61 per share a year ago.

zacks.com 2024 Aug 13
MRNS Stock News Image - businesswire.com

EL SEGUNDO, Calif.--(BUSINESS WIRE)--Pacific Defense, a leading provider of Modular Open Systems Approach (MOSA) products and mission solutions, announced their team to compete for the U.S. Army's CMOSS Mounted Form Factor (CMFF) program. Led by Pacific Defense, the CMFF team includes state-of-the-art industry technology leaders Thales Defense & Security Inc., BAE, Regal Technology Partners, Palantir and STC, an Arcfield Company. “Our company is purpose-built to drive the open-systems chang.

businesswire.com 2024 Aug 13
MRNS Stock News Image - businesswire.com

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the second quarter ended June 30, 2024. “Since launching ZTALMY in the U.S. two years ago, we have seen significant growth and adoption with strong revenue for the second quarter, underscoring the appreciation physicians, patients and caregivers have fo.

businesswire.com 2024 Aug 13
10 of 50